News Category
HeartBeam Inc. has joined a European consortium to lead the HEART-CHECK study, evaluating its portable ECG system for early detection of cardiac event...
Helus Pharma appoints Suresh Durgam, a veteran with over 20 years in CNS drug development, to its board, a move that could accelerate its late-stage p...
Tonix Pharmaceuticals will present its TNX-801 horsepox-based vaccine platform at a major European vaccine conference, highlighting a potential new to...
MindMaze Therapeutics' multi-site program shows that home-based rehabilitation using MindMotion triples motor-training dose and improves functional ou...
Quantum BioPharma (NASDAQ: QNTM) has received FDA approval to begin Phase 2 testing of Lucid-MS, a first-in-class multiple sclerosis drug that targets...
SS Innovations has submitted its response to the FDA's request for additional information on its 510(k) submission for the SSi Mantra surgical robotic...
MindBio Therapeutics has completed manufacturing of its next-generation Edge AI Intoxication Detection Kiosk, which uses voice analytics to identify i...
MindBio Therapeutics has finished manufacturing its next-generation AI-powered intoxication detection kiosk, which uses voice analysis to screen for i...
Retension Pharmaceuticals' upsized $45 million IPO provides critical funding to complete a Phase 2b trial and prepare for a Phase 3 trial of its lead ...
VERAXA Biotech presented first in vivo proof-of-concept data for its BiTAC-ADC platform, demonstrating significant tumor regression in a breast cancer...
A UK study reveals a potential method to stop lung cancer before diagnosis by clearing immune fog, though some mice still developed cancer, highlighti...
Scinai Immunotherapeutics' CDMO subsidiary signed a $5.1 million development and clinical manufacturing deal with a U.S. biopharma company, driving to...
VERAXA Biotech presented first in vivo proof-of-concept data for its BiTAC-ADC platform at the World ADC Congress, demonstrating significant tumor reg...
Leksum LLC has signed an agreement with the Medical University of Vienna to conduct preparatory work for Phase I/II clinical trials of LK-ICU, a thera...
A newly identified tumor-suppressive circuit linking SPRED2, p53, miR-506-3p, and KLF4 could offer fresh therapeutic targets for hepatocellular carcin...
Regentis Biomaterials will present at the 2026 ThinkEquity Conference, showcasing its GelrinC technology and recent clinical and regulatory advancemen...
Newron Pharmaceuticals has received written feedback from the FDA on the clinical hold at U.S. study centers for its Phase 3 ENIGMA-TRS 2 trial, as th...
Lantern Pharma's upcoming presentation at the ThinkEquity Conference underscores its leadership in AI-driven oncology drug development and offers inve...
Helus Pharma will host an investor presentation on October 21, 2026, highlighting its Phase 3 major depressive disorder program HLP003 and Phase 2 gen...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its neuroprotective Lucid-MS candidate into a Phase 2 trial, poten...
VERAXA Biotech's adoption of FDA-aligned New Approach Methodologies could accelerate clinical advancement, cut development costs and timelines, and si...
Nutriband Inc. has filed a non-provisional utility patent application with the USPTO for improved aversive formulations and coating methods that could...
Lantern Pharma (NASDAQ: LTRN) has received regulatory and IRB approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300, potentially ...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific to initiate a Phase 2 trial of Lucid-MS, a novel multiple sclero...
VERAXA Biotech's adoption of FDA-aligned New Approach Methodologies could significantly reduce animal testing, accelerate clinical advancement, and lo...
XORTX Therapeutics is advancing XORLO, a reformulated gout treatment, toward an FDA new drug application next year, aiming to address tolerability iss...
Quantum BioPharma's study start-up agreement with Thermo Fisher for its Lucid-MS Phase 2 trial in multiple sclerosis marks a key step toward clinical ...
Telomir Pharmaceuticals raises $5.6 million in a PIPE financing to fund clinical development of Telomir-Zn for triple-negative breast cancer, with bac...
NanoViricides will present at the NIBA 153rd Investment Conference, highlighting its broad-spectrum antiviral NV-387, which is in Phase 2 trials for E...
Quantum BioPharma's study start-up agreement with Thermo Fisher for its Phase 2 Lucid-MS trial signals progress toward a potential first-in-class mult...
New research reveals lymph-node-like structures in the skull's bone marrow, suggesting a local immune defense for the brain that could lead to innovat...
Kairos Pharma's ENV-105 combined with apalutamide demonstrated a statistically significant improvement in progression-free survival for metastatic cas...
AXIM Biotechnologies has submitted a 510(k) to the FDA for a next-generation, rapid point-of-care tear lactoferrin test for dry eye disease, which cou...
GeoVax's upcoming presentation at World Vaccine Congress Europe 2026 will highlight its next-generation MVA-X vaccine and continuous cell-line manufac...
The Global Markets Forum on October 7-8, 2026, offers investors direct access to management teams from companies listed worldwide across mining, biote...
NHS England's new rapid test that identifies a brain tumor's genetic makeup in about two hours instead of eight weeks could accelerate treatment decis...
Oncotelic Therapeutics invites scientists and AI developers to join its PDAOAI-powered BIO REBOOT initiative and announces two keynote presentations a...
NanoViricides has provided details on its Phase II trial of NV-387 Oral Gummies for Ebola, highlighting the potential of an oral antiviral that could ...
Certified-PEP's emphasis on U.S. manufacturing and independent batch testing through Vanguard Laboratory sets a new standard for transparency and trac...
Philip Ashton-Rickardt argues that effective scientific leaders must distinguish between attachment to an idea and commitment to a problem, and that f...
A blood-based method for identifying cancer neoantigens and T-cell activation could overcome the need for surgical tumor samples, potentially expandin...
Nutriband's five-year Nasdaq listing anniversary highlights its progress in developing an abuse-deterrent fentanyl patch, a product that could address...
Regentis Biomaterials is advancing a regenerative solution for knee cartilage repair that aims to overcome the short-term relief, long-term failure pr...
HealthLynked's partnership with DRCARE247 will embed virtual consultations into its AI-powered platform, potentially streamlining patient care from sy...
Stonegate Capital Partners updates coverage on Incannex Healthcare, highlighting the start of patient dosing in the DReAMzz trial and the company's 12...
Lantern Pharma's $4 million registered direct offering provides essential capital for its AI-native precision oncology programs, with potential for an...
Onco-Innovations has achieved a 300-gram API scale-up of its cancer drug candidate ONC010 with 99.3% purity and secured CAD$5 million in financing, ma...
Quantum BioPharma's Lucid-MS is entering a Phase 2 trial for multiple sclerosis, marking a critical step for the company's lead drug candidate, while ...
